Rigel Pharmaceuticals Inc (RIGL) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Rigel Pharmaceuticals Inc stock (RIGL) is currently trading at $26.13. Rigel Pharmaceuticals Inc PE ratio is 1.36. Rigel Pharmaceuticals Inc PS ratio (Price-to-Sales) is 1.66. Analyst consensus price target for RIGL is $51.20. WallStSmart rates RIGL as Buy.
- RIGL PE ratio analysis and historical PE chart
- RIGL PS ratio (Price-to-Sales) history and trend
- RIGL intrinsic value — DCF, Graham Number, EPV models
- RIGL stock price prediction 2025 2026 2027 2028 2029 2030
- RIGL fair value vs current price
- RIGL insider transactions and insider buying
- Is RIGL undervalued or overvalued?
- Rigel Pharmaceuticals Inc financial analysis — revenue, earnings, cash flow
- RIGL Piotroski F-Score and Altman Z-Score
- RIGL analyst price target and Smart Rating
Rigel Pharmaceuticals Inc
📊 No data available
Try selecting a different time range
RIGL Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Rigel Pharmaceuticals Inc (RIGL)
RIGL trades at a significant discount to its Graham intrinsic value of $911.66, offering a 96% margin of safety — a level value investors typically seek before buying.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Rigel Pharmaceuticals Inc (RIGL) · 10 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in return on equity, operating margin, price/sales. Concerns around peg ratio. Overall metrics suggest strong investment potential with favorable risk/reward.
Rigel Pharmaceuticals Inc (RIGL) Key Strengths (8)
Every $100 of shareholder equity generates $186 in profit
Keeps $33 of every $100 in revenue after operating costs
Earnings per share surging 1599.00% year-over-year
Keeps $125 of every $100 in revenue as net profit
90.07% of shares held by major funds and institutions
Paying $1.66 for every $1 of annual revenue
Trading at 1.23x book value, attractively priced
Strong revenue growth at 21.20% annually
Supporting Valuation Data
Rigel Pharmaceuticals Inc (RIGL) Areas to Watch (2)
PEG ratio is negative or unavailable
Small-cap company with higher risk but more growth potential
Rigel Pharmaceuticals Inc (RIGL) Detailed Analysis Report
Overall Assessment
This company scores 79/100 in our Smart Analysis, earning a B+ grade. Out of 10 metrics analyzed, 8 register as strengths (avg 9.3/10) while 2 fall into concern territory (avg 2.5/10). All four categories (Growth, Profitability, Valuation, and Quality) show healthy scores, indicating broadly sound fundamentals.
The Bull Case
The strongest argument centers on Return on Equity, Operating Margin, EPS Growth. Valuation metrics including Price/Sales (1.66), Price/Book (1.23) suggest the stock is attractively priced. Profitability is solid with Return on Equity at 185.90%, Operating Margin at 33.20%, Profit Margin at 124.70%. Growth metrics are encouraging with Revenue Growth at 21.20%, EPS Growth at 1599.00%.
The Bear Case
The primary concerns are PEG Ratio, Market Cap. Some valuation metrics including PEG Ratio (N/A) suggest expensive pricing.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether PEG Ratio improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 185.90% currently healthy but needing to be sustained. Third, growth sustainability, with Revenue Growth at 21.20% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a moderate risk investment. The weight of evidence leans positive, with more strengths than concerns. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
The combination of Return on Equity and Operating Margin makes a compelling case at current levels. The key risk is PEG Ratio, but the overall fundamental picture is positive with a clear path to maintaining or improving the current B+ grade.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
RIGL Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
RIGL's Price-to-Sales ratio of 1.66x trades at a deep discount to its historical average of 24.02x (20th percentile). The current valuation is 99% below its historical high of 230.16x set in Dec 2009, and 141% above its historical low of 0.69x in Aug 2019. Over the past 12 months, the PS ratio has compressed from ~2.2x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for Rigel Pharmaceuticals Inc (RIGL) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Rigel Pharmaceuticals Inc is a strong growth company balancing expansion with improving profitability. Revenue reached 294M with 21% growth year-over-year. Profit margins are strong at 124.7%, reflecting pricing power and operational efficiency.
Key Findings
ROE of 185.9% means the company generates strong returns on shareholder equity. Above 20% is considered top-tier.
Profit margin of 124.7% and operating margin of 33.2% demonstrate strong pricing power and operational efficiency.
What to Watch Next
Growth sustainability: can Rigel Pharmaceuticals Inc maintain 21%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Rigel Pharmaceuticals Inc.
Bottom Line
Rigel Pharmaceuticals Inc offers an attractive blend of growth (21% revenue expansion) and improving fundamentals. The company is transitioning from pure growth to profitable growth, a critical inflection point. Watch for sustained margin expansion as the key signal.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(22 last 3 months)
| Insider | Type | Shares |
|---|---|---|
MILLER, MICHAEL PATRICK Director | Buy | +12,000 |
Data sourced from SEC Form 4 filings
Last updated: 10:06:44 AM
About Rigel Pharmaceuticals Inc(RIGL)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat blood disorders, cancer, and rare immune diseases. The company is headquartered in South San Francisco, California.